SCHEMBL190796

SCHEMBL190796

CCOC(=O)Cc1cc(NC(=S)NC(=O)c2ccccc2)ncc1Br

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.49
KCNH2 Q12809 3/20 0.49
ALDH1A1 P00352 5/20 0.47
TSHR P16473 1/20 0.47
RAB9A P51151 6/20 0.46
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
PKM P14618 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
EPHX1 P07099 1/20 0.46
MAPT P10636 4/20 0.45
ALOX12 P18054 2/20 0.45
LMNA P02545 3/20 0.44
CYP1A2 P05177 3/20 0.43
CYP2C9 P11712 3/20 0.43
CYP2C19 P33261 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL191213 0.82 DPP4 (0.40) KCNH2ALDH1A1TSHRKMT2AMEN1
SCHEMBL191773 0.77 NPC1 (0.53) NPC1KCNH2ALDH1A1RAB9AKMT2A
SCHEMBL190965 0.76 RAB9A (0.45) NPC1KCNH2ALDH1A1RAB9AKMT2A
SCHEMBL2871030 0.76 SMN1; SMN2 (0.57) NPC1KCNH2ALDH1A1RAB9AKMT2A
SCHEMBL15012132 0.75 NPC1 (0.58) NPC1KCNH2ALDH1A1RAB9AKMT2A
SCHEMBL2659795 0.73 NPC1 (0.51) NPC1KCNH2ALDH1A1RAB9AKMT2A
SCHEMBL26854287 0.71 RAB9A (0.66) NPC1ALDH1A1RAB9AKMT2AMEN1
SCHEMBL190809 0.71 GCK (0.62) NPC1KCNH2ALDH1A1RAB9AKMT2A
SCHEMBL191169 0.71 MET (0.47) NPC1KCNH2ALDH1A1RAB9AKMT2A
SCHEMBL16439336 0.70 MAPT (0.51) NPC1ALDH1A1RAB9AKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 NPC1 1862/4885KCNH2 1689/4885ALDH1A1 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.